Lipocine Stock Leadership

LPCN -  USA Stock  

USD 1.09  0.04  3.54%

Lipocine employes about 13 people. The company is managed by 7 executives with total tenure of roughly 48 years, averaging almost 6.0 years of service per executive having 1.86 employees per reported executive. Inspection of Lipocine management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Lipocine future performance.
Additionally, see Stocks Correlation.

Lipocine Insiders 

 
Refresh
  Mahesh Patel  Chairman
Co-Founder, Chairman, CEO and Pres
  Gregory Bass  President
Executive Vice President Chief Commercial Officer
  Morgan Brown  President
CFO, Executive Vice President

Lipocine Return on Sales

(68.53)Share

Lipocine Management Team Effectiveness

Lipocine has return on total asset (ROA) of (27.03) % which means that it has lost $27.03 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (77.83) %, meaning that it created substantial loss on money invested by shareholders. Lipocine management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -96.63. The value of Return on Average Assets is estimated to slide to -0.91. Lipocine Net Current Assets as percentage of Total Assets are quite stable at the moment as compared to the past year. The company's current value of Net Current Assets as percentage of Total Assets is estimated at 72.44. Asset Turnover is expected to rise to 0.007389 this year, although the value of Return on Average Assets will most likely fall to (0.91) .

Lipocine Quarterly Total Assets

40.39 MillionShare
Lipocine Weighted Average Shares is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 60.08 Million. Weighted Average Shares Diluted is expected to rise to about 60.1 M this year, although the value of Issuance Purchase of Equity Shares will most likely fall to about 17.8 M.

Lipocine Workforce Comparison

Lipocine is rated second overall in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 26.0. Lipocine totals roughly 13.0 in number of employees claiming about 50% of stocks in Biotechnology industry.

Lipocine Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lipocine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lipocine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lipocine insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Lipocine Benchmark Summation

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Lowest value over a specified period line plots minimum value of Lipocine price series. View also all equity analysis or get more info about lowest value over a specified period math operators indicator.

Lipocine Notable Stakeholders

A Lipocine stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lipocine often face trade-offs trying to please all of them. Lipocine's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lipocine's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mahesh Patel - Co-Founder, Chairman, CEO and PresProfile
Gregory Bass - Executive Vice President Chief Commercial OfficerProfile
Morgan Brown - CFO, Executive Vice PresidentProfile
Richard Ono - DirectorProfile
Jeffrey Fink - DirectorProfile
Stephen Hill - Lead Independent DirectorProfile
John Higuchi - Non-Executive DirectorProfile

About Lipocine Management Performance

The success or failure of an entity such as Lipocine often depends on how effective the management is. Lipocine management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lipocine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lipocine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Investment(89.56) (96.63) 
Return on Average Assets(0.89) (0.91) 
Return on Average Equity(1.70) (1.74) 
Return on Invested Capital(4.72) (5.10) 
Return on Sales(66.77) (68.53) 
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. Lipocine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
The data published in Lipocine's official financial statements usually reflect Lipocine's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lipocine. For example, before you start analyzing numbers published by Lipocine accountants, it's critical to develop an understanding of what Lipocine's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Lipocine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lipocine's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lipocine's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lipocine. Please utilize our Beneish M Score to check the likelihood of Lipocine's management to manipulate its earnings.

Lipocine Workforce Analysis

Traditionally, organizations such as Lipocine use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lipocine within its industry.

Lipocine Manpower Efficiency

Return on Lipocine Manpower

Revenue Per Employee24.7 K
Revenue Per Executive0.0
Net Loss Per Employee1.3 M
Net Loss Per Executive2.7 M
Working Capital Per Employee2.1 M
Working Capital Per Executive4 M
Today, most investors in Lipocine Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lipocine's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lipocine per employee as a starting point in their analysis.

Per Employee

Lipocine Per Employee Growth Over Time

Net Income Per Employee

(1.34 Million)Share
Lipocine Net Income Per Employee is quite stable at the moment as compared to the past year. The company's current value of Net Income Per Employee is estimated at (1.34 Million)

Revenue Per Employee

24,692.08Share
Lipocine Revenue Per Employee is quite stable at the moment as compared to the past year. The company's current value of Revenue Per Employee is estimated at 24,692.08
Additionally, see Stocks Correlation. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.